Shares of CareDx (NASDAQ: CDNA) jumped 15.36% in after-hours trading on Tuesday following the release of the company's third-quarter financial results that significantly exceeded analyst expectations.

The transplant diagnostics company reported adjusted earnings per share of $0.28, which was more than double the analyst consensus estimate of $0.14. This represents a 100% increase from the same period last year when the company earned $0.14 per share. Revenue for the quarter came in at $100.1 million, surpassing the analyst forecast of $95.25 million and marking a 20.72% year-over-year growth from $82.88 million.

CareDx's strong performance was driven by a 19% increase in testing services revenue, which reached $72.2 million. The company also saw a 13% growth in testing services volume, processing 50,300 tests during the quarter. Additionally, CareDx reported a GAAP net income of $1.7 million, a significant improvement from a net loss of $10.6 million in the same quarter of 2024. The company's adjusted EBITDA more than doubled to $15.3 million from $6.9 million year-over-year.

Following these impressive results, CareDx raised its full-year 2025 revenue guidance to a range of $372 million to $376 million. The company also increased its adjusted EBITDA forecast to between $35 million and $39 million. The strong earnings report and improved outlook have clearly resonated with investors, driving the substantial after-hours stock price increase.